At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Mar 18, 2026 at 22:34 ET
Reviva Pharmaceuticals (RVPH) announced the pricing of a public offering of 6,666,667 shares of common stock and accompanying warrants to raise approximately $10 million in gross proceeds. The funds will be used to support the Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia, along with general corporate purposes. The offering includes dual tranches of warrants exercisable immediately at $1.50 per share, with differing expiration terms.
- Reviva is raising approximately $10 million through a public offering of 6,666,667 shares and warrants.
- Each share is sold with two warrants: Series G (5-year term) and Series H (12-month term), both exercisable at $1.50.
- The offering is priced at $1.50 per combined unit, below typical market thresholds for sustainable biotech financing.
- Proceeds will fund the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and general corporate needs.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access